189 related articles for article (PubMed ID: 26422284)
21. Analysis of Risk Factors for Abnormal Pulmonary Function in Pediatric Cancer Survivors.
Record E; Williamson R; Wasilewski-Masker K; Mertens AC; Meacham LR; Popler J
Pediatr Blood Cancer; 2016 Jul; 63(7):1264-71. PubMed ID: 27002916
[TBL] [Abstract][Full Text] [Related]
22. A New Modality for the Diagnosis of Bleomycin-induced Toxicity: Ultrasonography.
Doğan C; Cömert SŞ; Çağlayan B; Sağmen SB; Parmaksız ET; Kıral N; Fidan A; Salepçi B
Arch Bronconeumol (Engl Ed); 2018 Dec; 54(12):619-624. PubMed ID: 30032934
[TBL] [Abstract][Full Text] [Related]
23. Effect of Bleomycin Administration on the Development of Pulmonary Toxicity in Patients With Metastatic Germ Cell Tumors Receiving First-Line Chemotherapy: A Meta-Analysis of Randomized Studies.
Necchi A; Miceli R; Oualla K; Sonpavde G; Giannatempo P; Raggi D; Nicolai N; Boffi R; Busia A; Mariani L; Salvioni R
Clin Genitourin Cancer; 2017 Apr; 15(2):213-220.e5. PubMed ID: 27692810
[TBL] [Abstract][Full Text] [Related]
24. Life threatening lung toxicity induced by low doses of bleomycin in a patient with Hodgkin's disease.
Real E; Roca MJ; Viñuales A; Pastor E; Grau E
Haematologica; 1999 Jul; 84(7):667-8. PubMed ID: 10406918
[No Abstract] [Full Text] [Related]
25. [Examination of late pulmonary toxicity in children treated for malignancies].
Jordán Z; Tokodi Z; Németh A; Müller J; Csóka M; Mohl A; Erdélyi D; Kovács G
Orv Hetil; 2013 Mar; 154(9):345-50. PubMed ID: 23434884
[TBL] [Abstract][Full Text] [Related]
26. Risk of pulmonary toxicity of bleomycin and filgrastim.
Laprise-Lachance M; Lemieux P; Grégoire JP
J Oncol Pharm Pract; 2019 Oct; 25(7):1638-1644. PubMed ID: 30319063
[TBL] [Abstract][Full Text] [Related]
27. Short- and long-term outcomes after large pulmonary resection for germ cell tumors after bleomycin-combination chemotherapy.
Andrade RS; Kesler KA; Wilson JL; Brooks JA; Reichwage BD; Rieger KM; Einhorn LH; Brown JW
Ann Thorac Surg; 2004 Oct; 78(4):1224-8; discussion 1228-9. PubMed ID: 15464475
[TBL] [Abstract][Full Text] [Related]
28. Bleomycin induced pulmonary toxicity in patients with germ cell tumours.
Usman M; Faruqui ZS; ud Din N; Zahid KF
J Ayub Med Coll Abbottabad; 2010; 22(3):35-7. PubMed ID: 22338413
[TBL] [Abstract][Full Text] [Related]
29. Bleomycin associated pulmonary toxicity: is perioperative oxygen restriction necessary?
Donat SM; Levy DA
J Urol; 1998 Oct; 160(4):1347-52. PubMed ID: 9751352
[TBL] [Abstract][Full Text] [Related]
30. Elevation of the erythrocyte sedimentation rate precedes exacerbation of bleomycin-induced pulmonary toxicity: report of two cases and review of literature.
Higa GM; AlKhouri N; Auber ML
Pharmacotherapy; 1997; 17(6):1315-21. PubMed ID: 9399618
[TBL] [Abstract][Full Text] [Related]
31. Pulmonary Function After Treatment for Embryonal Brain Tumors on SJMB03 That Included Craniospinal Irradiation.
Green DM; Merchant TE; Billups CA; Stokes DC; Broniscer A; Bartels U; Chintagumpala M; Hassall TE; Gururangan S; McCowage GB; Heath JA; Cohn RJ; Fisher MJ; Srinivasan A; Robinson GW; Gajjar A
Int J Radiat Oncol Biol Phys; 2015 Sep; 93(1):47-53. PubMed ID: 26279023
[TBL] [Abstract][Full Text] [Related]
32. [Risk factors for lung toxicity in pediatric cancer survivors].
López Andreu JA; Compte Torrero L; Ferrís Tortajada J; Domenech Clar R; Pérez Tarazona S; Pellicer Porres C; Cortina Orts H; Roqués Serradilla JM
An Esp Pediatr; 1999 Nov; 51(5):505-11. PubMed ID: 10652802
[TBL] [Abstract][Full Text] [Related]
33. Evaluation of diffusing capacity in patients with a restrictive lung disease.
Stam H; Splinter TA; Versprille A
Chest; 2000 Mar; 117(3):752-7. PubMed ID: 10713002
[TBL] [Abstract][Full Text] [Related]
34. Late pulmonary toxicity of bleomycin.
Willenbacher W; Mumm A; Bartsch HH
J Clin Oncol; 1998 Sep; 16(9):3205. PubMed ID: 9738596
[No Abstract] [Full Text] [Related]
35. Bleomycin and pulmonary screening: many questions, few answers.
Duncan CN
Pediatr Blood Cancer; 2014 Sep; 61(9):1527-8. PubMed ID: 24810221
[No Abstract] [Full Text] [Related]
36. Carbon monoxide diffusing capacity is a poor predictor of clinically significant bleomycin lung. New Zealand Clinical Oncology Group.
McKeage MJ; Evans BD; Atkinson C; Perez D; Forgeson GV; Dady PJ
J Clin Oncol; 1990 May; 8(5):779-83. PubMed ID: 1692088
[TBL] [Abstract][Full Text] [Related]
37. Bleomycin pulmonary toxicity in adult Saudi patients with Hodgkin's lymphoma.
Al-Jizani WA; Al-Mansour MM; Al-Fayea TM; Shafi RU; Kazkaz GA; Bayer AM; Al-Foheidi ME; Ibrahim EM
Future Oncol; 2015; 11(15):2149-57. PubMed ID: 26235180
[TBL] [Abstract][Full Text] [Related]
38. A longitudinal analysis of early lung function trajectory in survivors of childhood Hodgkin lymphoma.
Zheng K; Bassal M; Mitsakakis N; Cepalo T; Hamid JS; Momoli F; Reisman J; Nair V; Radhakrishnan D
Cancer Rep (Hoboken); 2023 Jan; 6(1):e1661. PubMed ID: 35760768
[TBL] [Abstract][Full Text] [Related]
39. Pulmonary functions testing in patients with rheumatoid arthritis.
Avnon LS; Manzur F; Bolotin A; Heimer D; Flusser D; Buskila D; Sukenik S; Abu-Shakra M
Isr Med Assoc J; 2009 Feb; 11(2):83-7. PubMed ID: 19432035
[TBL] [Abstract][Full Text] [Related]
40. Role of pulmonary function tests in the prevention of bleomycin pulmonary toxicity during chemotherapy for metastatic testicular teratoma.
Lucraft HH; Wilkinson PM; Stretton TB; Read G
Eur J Cancer Clin Oncol; 1982 Feb; 18(2):133-9. PubMed ID: 6178590
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
